Kepos Capital’s Standard BioTools LAB Stock Holding History

Kepos Capital’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-50,000	Closed	-$226K	–	461
2021 Q1	$226K	Hold	50,000	–	–	0.01%	363
2020 Q4	$300K	Hold	50,000	–	–	0.03%	265
2020 Q3	$372K	Buy	+50,000	New	+$345K	0.04%	193

Other funds holding LAB

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Kepos Capital's LAB Position: Q2 2021 in Review

Kepos Capital sold out of Standard BioTools (LAB) in Q2 2021, closing a stake of 50,000 shares — an estimated $226K sold.

Kepos Capital first reported a position in LAB in Q3 2020 and held it in 3 quarters. The position peaked at $372K in Q3 2020. 113 funds tracked by Wall St. Rank hold LAB as of Q2 2021.

Kepos Capital reported no remaining Standard BioTools position as of Q2 2021 after selling out during the quarter.
Kepos Capital sold 50,000 Standard BioTools shares in Q2 2021, an estimated $226K.
Kepos Capital first reported a position in Standard BioTools in Q3 2020 and held it in 3 quarters.
Kepos Capital's Standard BioTools position peaked at $372K in Q3 2020.
113 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2021.

Based on Kepos Capital's 13F filing for Q2 2021, filed 12 Aug 2021.